Source:http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/1632
| Predicate | Object |
|---|---|
| rdf:type | |
| rdfs:label |
Ondansetron Hydrochloride (Injection, Solution)
|
| dailymed-instance:dosage |
Prevention of Chemotherapy-Induced
Nausea and Vomiting: Adult Dosing: The recommended I.V.
dosage of ondansetron for adults is a single 32 mg dose or three 0.15
mg/kg doses. A single 32 mg dose is infused over 15 minutes beginning
30 minutes before the start of emetogenic chemotherapy. The recommended
infusion rate should not be exceeded (see OVERDOSAGE). With the three-dose
(0.15 mg/kg) regimen, the first dose is infused over 15 minutes beginning
30 minutes before the start of emetogenic chemotherapy. Subsequent
doses (0.15 mg/kg) are administered 4 and 8 hours after the first
dose of ondansetron. Ondansetron Injection,
USP should not be mixed with solutions for which physical and chemical
compatibility have not been established. In particular, this applies
to alkaline solutions as a precipitate may form. Vial: DILUTE BEFORE USE FOR PREVENTION OF CHEMOTHERAPY-INDUCED
NAUSEA AND VOMITING. Ondansetron Injection, USP should be
diluted in 50 mL of 5% Dextrose Injection or 0.9% Sodium Chloride
Injection before administration. Pediatric Dosing: On the basis
of the available information (see CLINICAL TRIALS: Pediatric Studies
and CLINICAL PHARMACOLOGY: Pharmacokinetics), the dosage in pediatric
cancer patients 4 to 18 years of age should be three 0.15 mg/kg doses.
The first dose is to be administered 30 minutes before the start of
moderately to highly emetogenic chemotherapy, subsequent doses (0.15
mg/kg) are administered 4 and 8 hours after the first dose of ondansetron.
The drug should be infused intravenously over 15 minutes. Little information
is available about dosage in pediatric cancer patients younger than
6 months of age. Dosing information for pediatric
cancer patients 6 months to 48 months of age is approved for GlaxoSmithKline
Corporation's ondansetron injection. However, due to GlaxoSmithKline's
marketing exclusivity rights, this drug product is not labeled for
use in this subpopulation of pediatric patients. Vial: DILUTE BEFORE USE. Ondansetron Injection,
USP should be diluted in 50 mL of 5% Dextrose Injection or 0.9% Sodium
Chloride Injection before administration. Geriatric Dosing: The dosage recommendation
is the same as for the general population. Prevention of Postoperative Nausea and Vomiting: Adult Dosing: The recommended I.V. dosage of ondansetron for adults is 4 mg undiluted administered intravenously in
not less than 30 seconds, preferably over 2 to 5 minutes, immediately
before induction of anesthesia, or postoperatively if the patient
experiences nausea and/or vomiting occurring shortly after surgery.
Alternatively, 4 mg undiluted may be administered intramuscularly as a single injection for adults.
While recommended as a fixed dose for patients weighing more than
40 kg, few patients above 80 kg have been studied. In patients who
do not achieve adequate control of postoperative nausea and vomiting
following a single, prophylactic, preinduction, I.V. dose of ondansetron
4 mg, administration of a second I.V. dose of 4 mg ondansetron postoperatively
does not provide additional control of nausea and vomiting. Vial: REQUIRES NO DILUTION FOR ADMINISTRATION FOR POSTOPERATIVE
NAUSEA AND VOMITING. Pediatric Dosing: The recommended
I.V. dosage of ondansetron for pediatric surgical patients (2 to 12
years of age) is a single 0.1 mg/kg dose for pediatric patients weighing
40 kg or less, or a single 4 mg dose for pediatric patients weighing
more than 40 kg. The rate of administration should not be less than
30 seconds, preferably over 2 to 5 minutes immediately prior to or
following anesthesia induction, or postoperatively if the patient
experiences nausea and/or vomiting occurring shortly after surgery.
Prevention of further nausea and vomiting was only studied in patients
who had not received prophylactic ondansetron. Dosing information for pediatric surgical patients 1 month to 24
months of age is approved for GlaxoSmithKline Corporation's
ondansetron injection. However, due to GlaxoSmithKline's marketing
exclusivity rights, this drug product is not labeled for use in this
subpopulation of pediatric patients. Vial: REQUIRES NO DILUTION FOR ADMINISTRATION FOR POSTOPERATIVE NAUSEA
AND VOMITING. Geriatric Dosing: The dosage recommendation
is the same as for the general population. Dosage Adjustment for Patients With Impaired Renal
Function: The dosage recommendation is the same as for
the general population. There is no experience beyond first-day administration
of ondansetron. Dosage
Adjustment for Patients With Impaired Hepatic Function: In patients with severe hepatic impairment (Child- Pughscore of 10 or greater), a single maximal daily dose of 8 mg to
be infused over 15 minutes beginning 30 minutes before the start of
the emetogenic chemotherapy is recommended. There is no experience
beyond first-day administration of ondansetron. Stability: Ondansetron Injection,
USP is stable at room temperature under normal lighting conditions
for 48 hours after dilution with the following I.V. fluids: 0.9% Sodium
Chloride Injection, 5% Dextrose Injection, 5% Dextrose and 0.9% Sodium
Chloride Injection, 5% Dextrose and 0.45% Sodium Chloride Injection,
and 3% Sodium Chloride Injection. Although
Ondansetron Injection, USP is chemically and physically stable when
diluted as recommended, sterile precautions should be observed because
diluents generally do not contain preservative. After dilution, do
not use beyond 24 hours. Note: Parenteral drug products should be inspected visually
for particulate matter and discoloration before administration whenever
solution and container permit. Precaution: Occasionally, ondansetron
precipitates at the stopper/vial interface in vials stored upright.
Potency and safety are not affected. If a precipitate is observed,
resolubilize by shaking the vial vigorously.
|
| dailymed-instance:descripti... |
The active ingredient is ondansetron hydrochloride
(HCl), the racemic form of ondansetron and a selective blocking agent
of the serotonin 5-HTreceptor type. Chemically it is
(��) 1, 2, 3, 9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-
yl)methyl]-4H-carbazol-4-one, monohydrochloride, dihydrate. It has
the following structural formula: The empirical formula is CHNO���HCl���2HO, representing a molecular weight
of 365.9. Ondansetron HCl is a white to off-white
powder that is soluble in water and normal saline. Sterile Injection for Intravenous (I.V.)
or Intramuscular (I.M.) Administration: Each 1 mL of aqueous
solution in the 2 mL single-dose vial contains 2 mg of ondansetron
as the hydrochloride dihydrate; 9 mg of sodium chloride, USP; and
0.46 mg of citric acid anhydrous, USP and 0.25 mg of sodium citrate
dihydrate, USP as buffers in Water for Injection, USP. Each 1 mL of aqueous solution in the 20 mL multidose vial
contains 2 mg of ondansetron as the hydrochloride dihydrate; 8.3 mg
of sodium chloride, USP; 0.46 mg of citric acid anhydrous, USP and
0.25 mg of sodium citrate dihydrate, USP as buffers; and 1.2 mg of
methylparaben, NF and 0.15 mg of propylparaben, NF as preservatives
in Water for Injection, USP. Ondansetron Injection,
USP is a clear, colorless, nonpyrogenic, sterile solution. The pH
of the injection solution is 3.3 to 4.0.
|
| dailymed-instance:clinicalP... |
Pharmacodynamics: Ondansetron is a selective 5-HTreceptor antagonist.
While ondansetron's mechanism of action has not been fully characterized,
it is not a dopamine-receptor antagonist. Serotonin receptors of the
5-HTtype are present both peripherally on vagal nerve
terminals and centrally in the chemoreceptor trigger zone of the area
postrema. It is not certain whether ondansetron's antiemetic action
in chemotherapy-induced nausea and vomiting is mediated centrally,
peripherally, or in both sites. However, cytotoxic chemotherapy appears
to be associated with release of serotonin from the enterochromaffin
cells of the small intestine. In humans, urinary 5-HIAA (5-hydroxyindoleacetic
acid) excretion increases after cisplatin administration in parallel
with the onset of vomiting. The released serotonin may stimulate the
vagal afferents through the 5-HTreceptors and initiate
the vomiting reflex. In animals, the emetic
response to cisplatin can be prevented by pretreatment with an inhibitor
of serotonin synthesis, bilateral abdominal vagotomy and greater splanchnic
nerve section, or pretreatment with a serotonin 5-HTreceptor
antagonist. In normal volunteers, single I.V.
doses of 0.15 mg/kg of ondansetron had no effect on esophageal motility,
gastric motility, lower esophageal sphincter pressure, or small intestinal
transit time. In another study in six normal male volunteers, a 16
mg dose infused over 5 minutes showed no effect of the drug on cardiac
output, heart rate, stroke volume, blood pressure, or electrocardiogram
(ECG). Multiday administration of ondansetron has been shown to slow
colonic transit in normal volunteers. Ondansetron has no effect on
plasma prolactin concentrations. In a gender-balanced
pharmacodynamic study (n = 56), ondansetron 4 mg administered intravenously
or intramuscularly was dynamically similar in the prevention of nausea
and vomiting using the ipecacuanha model of emesis. Ondansetron does not alter the respiratory depressant effects produced
by alfentanil or the degree of neuromuscular blockade produced by
atracurium. Interactions with general or local anesthetics have not
been studied. Pharmacokinetics: Ondansetron is extensively metabolized in humans, with approximately
5% of a radiolabeled dose recovered as the parent compound from the
urine. The primary metabolic pathway is hydroxylation on the indole
ring followed by glucuronide or sulfate conjugation. Although some nonconjugated metabolites have pharmacologic activity,
these are not found in plasma at concentrations likely to significantly
contribute to the biological activity of ondansetron. In vitro metabolism studies
have shown that ondansetron is a substrate for human hepatic cytochrome
P-450 enzymes, including CYP1A2, CYP2D6, and CYP3A4. In terms of overall
ondansetron turnover, CYP3A4 played the predominant role. Because
of the multiplicity of metabolic enzymes capable of metabolizing ondansetron,
it is likely that inhibition or loss of one enzyme (e.g., CYP2D6 genetic
deficiency) will be compensated by others and may result in little
change in overall rates of ondansetron elimination. Ondansetron elimination
may be affected by cytochrome P-450 inducers. In a pharmacokinetic
study of 16 epileptic patients maintained chronically on CYP3A4 inducers,
carbamazepine or phenytoin, reduction in AUC, Cand
Tof ondansetron was observed.This resulted
in a significant increase in clearance. However, on the basis of available
data, no dosage adjustment for ondansetron is recommended (see PRECAUTIONS:
Drug Interactions). In humans, carmustine, etoposide,
and cisplatin do not affect the pharmacokinetics of ondansetron. In normal adult volunteers, the following mean pharmacokinetic
data have been determined following a single 0.15 mg/kg I.V. dose. A reduction in clearance and increase in elimination
half-life are seen in patients over 75 years of age. In clinical trials
with cancer patients, safety and efficacy were similar in patients
over 65 years of age and those under 65 years of age; there was an
insufficient number of patients over 75 years of age to permit conclusions
in that age group. No dosage adjustment is recommended in the elderly. In patients with mild-to-moderate hepatic impairment,
clearance is reduced twofold and mean half-life is increased to 11.6
hours compared to 5.7 hours in normals. In patients with severe hepatic
impairment (Child-Pughscore of 10 or greater), clearance
is reduced twofold to threefold and apparent volume of distribution
is increased with a resultant increase in half-life to 20 hours. In
patients with severe hepatic impairment, a total daily dose of 8 mg
should not be exceeded. Due to the very small
contribution (5%) of renal clearance to the overall clearance, renal
impairment was not expected to significantly influence the total clearance
of ondansetron. However, ondansetron mean plasma clearance was reduced
by about 41% in patients with severe renal impairment (creatinine
clearance<30 mL/min). This reduction in clearance is variable
and was not consistent with an increase in half-life. No reduction
in dose or dosing frequency in these patients is warranted. In adult cancer patients, the mean elimination half-life
was 4 hours, and there was no difference in the multidose pharmacokinetics
over a 4 day period. In a study of 21 pediatric cancer patients (4
to 18 years of age) who received three I.V. doses of 0.15 mg/kg of
ondansetron at 4 hour intervals, patients older than 15 years of age
exhibited ondansetron pharmacokinetic parameters similar to those
of adults. Patients 4 to 12 years of age generally showed higher clearance
and somewhat larger volume of distribution than adults. Most pediatric
patients younger than 15 years of age with cancer had a shorter (2.4
hours) ondansetron plasma half-life than patients older than 15years
of age. It is not known whether these differences in ondansetron plasma
half-life may result in differences in efficacy between adults and
some young pediatric patients (see CLINICAL TRIALS: Pediatric Studies). Pharmacokinetic information for pediatric cancer patients
6 months to 48 months of age is approved for GlaxoSmithKline Corporation's
ondansetron injection. However, due to GlaxoSmithKline's marketing
exclusivity rights, this drug product is not labeled for use in this
subpopulation of pediatric patients. In a study
of 21 pediatric patients (3 to 12 years of age) who were undergoing
surgery requiring anesthesia for a duration of 45 minutes to 2 hours,
a single I.V. dose of ondansetron, 2 mg (3 to 7 years) or 4 mg (8
to 12 years), was administered immediately prior to anesthesia induction.
Mean weight-normalized clearance and volume of distribution values
in these pediatric surgical patients were similar to those previously
reported for young adults. Meanterminal half-life was slightly reduced
in pediatric patients (range, 2.5 to 3 hours) in comparison with adults
(range, 3 to 3.5 hours). In general, surgical and cancer pediatric patients
younger than 18 years tend to have a higher ondansetron clearance
compared to adults leading to a shorter half-life in most pediatric
patients. In patients 1 month to 4 months of age, a longer half-life
was observed due to the higher volume of distribution in this age
group. Pharmacokinetic information for pediatric
surgical patients 1 month to 24 months of age is approved for GlaxoSmithKline
Corporation's ondansetron injection. However, due to GlaxoSmithKline's
marketing exclusivity rights, this drug product is not labeled for
use in this subpopulation of pediatric patients. In normal volunteers (19 to 39 years old, n = 23), the peak plasma
concentration was 264 ng/mL following a single 32 mg dose administered
as a 15 minute I.V. infusion. The mean elimination half-life was 4.1
hours. Systemic exposure to 32 mg of ondansetron was not proportional
to dose as measured by comparing dose-normalized AUC values to an
8 mg dose. This is consistent with a small decrease in systemic clearance
with increasing plasma concentrations. A study
was performed in normal volunteers (n = 56) to evaluate the pharmacokinetics
of a single 4 mg dose administered as a 5 minute infusion compared
to a single intramuscular injection. Systemic exposure as measured
by mean AUC was equivalent, with values of 156 [95% CI 136, 180] and
161 [95% CI 137, 190] ng���h/mL for I.V. and I.M. groups, respectively.
Mean peak plasma concentrations were 42.9 [95% CI 33.8, 54.4] ng/mL
at 10 minutes after I.V. infusion and 31.9 [95% CI 26.3, 38.6] ng/mL
at 41 minutes after I.M. injection. The mean elimination half-life
was not affected by route of administration. Plasma protein binding of ondansetron as measured in vitro was 70% to 76%, with binding
constant over the pharmacologic concentration range (10 to 500 ng/mL).
Circulating drug also distributes into erythrocytes. A positive lymphoblast transformation test to ondansetron has been
reported, which suggests immunologic sensitivity to ondansetron.
|
| dailymed-instance:activeIng... | |
| dailymed-instance:contraind... |
Ondansetron Injection, USP is contraindicated for
patients known to have hypersensitivity to the drug.
|
| dailymed-instance:supply |
Ondansetron Injection,
USP, 2 mg/mL, is supplied as follows: NDC 0409-4755-01 2 mL single-dose vials, carton of 5 NDC 0409-4755-02 2 mL single-dose vials, carton of 10 NDC 0409-4759-01 20 mL multidose vials, carton of 1 Store at 20 - 25��C (68
- 77��F). [See USP Controlled Room Temperature.] Product may also be stored in a refrigerator, 2 -
8��C (36 - 46��F). Retain in carton until time of use. Protect
from light.
|
| dailymed-instance:activeMoi... | |
| dailymed-instance:inactiveI... | |
| dailymed-instance:precautio... |
General:: Ondansetron is not a drug that stimulates gastric
or intestinal peristalsis. It should not be used instead of nasogastric
suction. The use of ondansetron in patients following abdominal surgery
or in patients with chemotherapy-induced nausea and vomiting may mask
a progressive ileus and/or gastric distention. Rarely and predominantly with intravenous ondansetron, transient
ECG changes including QT interval prolongation have been reported.<br/>Drug Interactions:: Ondansetron does not itself appear to induce or inhibit
the cytochrome P-450 drug-metabolizing enzyme system of the liver
(see CLINICAL PHARMACOLOGY, Pharmacokinetics). Because ondansetron
is metabolized by hepatic cytochrome P-450 drug-metabolizing enzymes
(CYP3A4, CYP2D6, CYP1A2), inducers or inhibitors of these enzymes
may change the clearance and, hence, the half-life of ondansetron.
On the basis of limited available data, no dosage adjustment is recommended
for patients on these drugs. Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin,
carbamazepine and rifampicin), the clearance of ondansetron was significantly
increased and ondansetron blood concentrations were decreased. However,
on the basis of available data, no dosage adjustment for ondansetron
is recommended for patients on these drugs. Tramadol: Although no pharmacokinetic drug interaction between ondansetron
and tramadol has been observed, data from 2 small studies indicate
that ondansetron may be associated with an increase in patient controlled
administration of tramadol. Chemotherapy: Tumor response to
chemotherapy in the P 388 mouse leukemia model is not affected by
ondansetron. In humans, carmustine, etoposide and cisplatin do not
affect the pharmacokinetics of ondansetron. In a crossover study in 76 pediatric patients, I.V. ondansetron did
not increase blood levels of high dose methotrexate.<br/>Carcinogenesis, Mutagenesis, Impairment of Fertility:: Carcinogenic effects were not seen in 2 year studies
in rats and mice with oral ondansetron doses up to 10 and 30 mg/kg
per day, respectively. Ondansetron was not mutagenic in standard tests
for mutagenicity. Oral administration of ondansetron up to 15 mg/kg
per day did not affect fertility or general reproductive performance
of male and female rats.<br/>Pregnancy:: Teratogenic Effects: Pregnancy Category B. Reproduction studies have been performed in
pregnant rats and rabbits at I.V. doses up to 4 mg/kg per day and
have revealed no evidence of impaired fertility or harm to the fetus
due to ondansetron. There are, however, no adequate and well-controlled
studies in pregnant women. Because animal reproduction studies are
not always predictive of human response, this drug should be used
during pregnancy onlyif clearly needed.<br/>Nursing Mothers:: Ondansetron is excreted in the breast milk of rats.
It is not known whether ondansetron is excreted in human milk. Because
many drugs are excreted in human milk, caution should be exercised
when ondansetron is administered to a nursing woman.<br/>Pediatric Use:: Little information is available about the use of
ondansetron in pediatric surgical patients younger than 1 month of
age. Little information is available about the use of ondansetron
in pediatric cancer patients younger than 6 months of age. The clearance of ondansetron in pediatric patients 1 month
to 4 months of age is slower and the half-life is ~2.5 fold longer
than patients who are>4 to 24 months of age. As a precaution, it
is recommended that patients less than 4 months of age receiving this
drug be closely monitored. (See CLINICAL PHARMACOLOGY: Pharmacokinetics.) The frequency and type of adverse events reported in pediatric
patients receiving ondansetron were similar to those in patients receiving
placebo.<br/>Geriatric Use:: Of the total number of subjects enrolled in cancer
chemotherapy-induced and postoperative nausea and vomiting in US-
and foreign-controlled clinical trials, 862 were 65 years of age and
over. No overall differences in safety or effectiveness were observed
between these subjects and younger subjects, and other reported clinical
experience has not identified differences in responses between the
elderly and younger patients, but greater sensitivity of some older
individuals cannot be ruled out. Dosage adjustment is not needed in
patients over the age of 65 (see CLINICAL PHARMACOLOGY).
|
| dailymed-instance:overdosag... |
There is no specific antidote for ondansetron overdose.
Patients should be managed with appropriate supportive therapy. Individual
doses as large as 150 mg and total daily dosages (three doses) as
large as 252 mg have been administered intravenously without significant
adverse events. These doses are more than 10 times the recommended
daily dose. In addition to the adverse events
listed above, the following events have been described in the setting
of ondansetron overdose: "Sudden blindness" (amaurosis) of 2 to 3
minutes' duration plus severe constipation occurred in one patient
that was administered 72 mg of ondansetron intravenously as a single
dose. Hypotension (and faintness) occurred in another patient that
took 48 mg of oral ondansetron. Following infusion of 32 mg over only
a 4 minute period, a vasovagal episode with transient second-degree
heart block was observed. In all instances, the events resolved completely.
|
| dailymed-instance:genericMe... |
Ondansetron Hydrochloride
|
| dailymed-instance:fullName |
Ondansetron Hydrochloride (Injection, Solution)
|
| dailymed-instance:adverseRe... |
Chemotherapy-Induced Nausea
and Vomiting: The adverse events in Table 11 have been reported
in adults receiving ondansetron at a dosage of three 0.15 mg/kg doses
or as a single 32 mg dose in clinical trials. These patients were
receiving concomitant chemotherapy, primarily cisplatin, and I.V.
fluids. Most were receiving a diuretic. The following have been reported during controlled
clinical trials: Cardiovascular: Rare cases of angina (chest pain), electrocardiographic
alterations, hypotension, and tachycardia have been reported. In many
cases, the relationship to Ondansetron Injection, USP was unclear. Gastrointestinal: Constipation has been reported in 11% of chemotherapy patients receiving
multiday ondansetron. Hepatic: In comparative trials
in cisplatin chemotherapy patients with normal baseline values of
aspartate transaminase (AST) and alanine transaminase (ALT), these
enzymes have been reported to exceed twice the upper limit of normal
in approximately 5% of patients. The increases were transient and
did not appear to be related to dose or duration oftherapy. On repeat
exposure, similar transient elevations in transaminase values occurred
in some courses, but symptomatic hepatic disease did not occur. Integumentary: Rash has occurred in approximately 1% of patients receiving ondansetron. Neurological: There have been rare reports consistent with, but not diagnostic
of, extrapyramidal reactions in patients receiving ondansetron, and
rare cases of grand mal seizure. The relationship to ondansetron was
unclear. Other: Rare cases of hypokalemia have been reported. The relationship to
Ondansetron Injection, USP was unclear. Postoperative Nausea and Vomiting: The
adverse events in Table 12 have been reported in���2% of adults
receiving ondansetron at a dosage of 4 mg I.V. over 2 to 5 minutes
in clinical trials. Rates of these events were not significantly different
in the ondansetron and placebo groups. These patients were receiving
multiple concomitant perioperative and postoperative medications. Pediatric Use: The adverse events in Table 13 were the most commonly reported adverse
events in pediatric patients receiving ondansetron (a single 0.1 mg/kg
dose for pediatric patients weighing 40 kg or less, or 4 mg for pediatric
patients weighing more than 40 kg) administered intravenously over
at least 30 seconds. Rates of these events were not significantly
different in the ondansetron and placebo groups. These patients were
receiving multiple concomitant perioperative and postoperative medications. Adverse events information reported in pediatric
surgical patients 1 month to 24 months of age is approved for GlaxoSmithKline
Corporation's ondansetron injection. However, due to GlaxoSmithKline's
marketing exclusivity rights, this drug product is not labeled for
use in this subpopulation of pediatric patients. Observed During Clinical Practice: In addition to adverse events reported from clinical trials, the
following events have been identified during post-approval use of
intravenous formulations of ondansetron. Because they are reported
voluntarily from a population of unknown size, estimates of frequency
cannot be made. The events have been chosen for inclusion due to a
combination of their seriousness, frequency of reporting, or potential
causal connection to ondansetron. Cardiovascular: Arrhythmias (including
ventricular and supraventricular tachycardia, premature ventricular
contractions, and atrial fibrillation), bradycardia, electrocardiographic
alterations (including second-degree heart block, QT interval prolongation,
and ST segment depression), palpitations, and syncope. General: Flushing. Rare cases of hypersensitivity reactions, sometimes severe
(e.g., anaphylaxis/anaphylactoid reactions, angioedema, bronchospasm,
cardiopulmonary arrest, hypotension, laryngeal edema, laryngospasm,
shock, shortness of breath, stridor) have also been reported. Hepatobiliary: Liver enzyme abnormalities have been reported. Liver failure and
death have been reported in patients with cancer receiving concurrent
medications including potentially hepatotoxic cytotoxic chemotherapy
and antibiotics. The etiology of the liver failure is unclear. Local Reactions: Pain, redness, and burning at site of injection. Lower Respiratory: Hiccups Neurological: Oculogyric crisis, appearing alone, as well as with other dystonic
reactions. Skin: Urticaria Special Senses: Transient dizziness
during or shortly after I.V. infusion. Eye Disorders: Transient blurred
vision, in some cases associated with abnormalities of accommodation.
Cases of transient blindness, predominantly during intravenous administration,
have been reported. These cases of transient blindness were reported
to resolve within a few minutes up to 48 hours.
|
| dailymed-instance:warning |
Hypersensitivity reactions have been reported in
patients who have exhibited hypersensitivity to other selective 5-HTreceptor antagonists.
|
| dailymed-instance:represent... | |
| dailymed-instance:routeOfAd... | |
| dailymed-instance:name |
Ondansetron Hydrochloride
|